Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Ganirelix · Ganirelix Acetate

Peptide · Antagonist · developed by Organon Usa Organon

Approved FDA, Jul 1999
OGN Developer
1 Registered trials

What is Ganirelix?

Ganirelix is a synthetic peptide given by subcutaneous injection during controlled ovarian stimulation, used in the context of fertility treatment.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Ganirelix Acetate
Drug type
Peptide
Mechanism
Antagonist
Therapy area
Women's health
Developer
Organon Usa Organon (OGN)
FDA status
Approved as Ganirelix Acetate (July 29, 1999), NDA021057

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT00703014 N/A Pregnancy Completed OGN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

NeonatesPregnancy

More from Organon Usa Organon

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the OGN page.

Follow OGN, the company behind Ganirelix

See OGN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

OGN catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.